Abstract
Incretin-based therapies, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 inhibitors (DPP-4i), have been hypothesized to exert beneficial effects on COVID-19 outcomes due to anti-inflammatory properties. In this population-based cohort study, we retrieved data from nationwide registries on all individuals diagnosed with severe acute respiratory syndrome coronavirus 2 infection up to 1 November 2020. For individuals with diabetes, we examined the impact of use of GLP-1 RAs (n = 370) and DPP-4i (n = 284) compared with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) (n = 342) on risk of hospital admission and severe outcomes. Relative risks (RRs) were calculated after applying propensity score weighted methods to control for confounding. Current users of GLP-1 RAs had an adjusted RR of 0.89 (95% confidence interval 0.34-2.33), while users of DPP-4i had an adjusted RR of 2.42 (95% confidence interval 0.99-5.89) for 30-day mortality compared with SGLT-2i use. Further, use of GLP-1 RAs or DPP-4i compared with SGLT-2i was not associated with decreased risk of hospital admission. Thus, use of incretin-based therapies in individuals with diabetes and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was not associated with improved clinical outcomes.
Original language | English |
---|---|
Article number | 14329 |
Journal | Diabetes, Obesity and Metabolism |
Volume | 23 |
Issue number | 6 |
Pages (from-to) | 1397-1401 |
Number of pages | 5 |
ISSN | 1462-8902 |
DOIs | |
Publication status | Published - 1 Jun 2021 |
Keywords
- DPP-4 inhibitor
- GLP-1 analogue
- SGLT-2 inhibitor
- antidiabetic drug
- population study
- SGLT‐
- 1 analogue
- 2 inhibitor
- GLP‐
- 4 inhibitor
- DPP‐